Key result
Valsartan improves vascular remodeling, endothelial function, and atherosclerosis markers across preclinical models.
Why the study?
Valsartan's effects on vasoconstriction, proliferation, remodelling, endothelial function, thrombogenesis, inflammation, and atherosclerosis have been demonstrated in animal models but require clinical confirmation.
Does not support clinical use; leaves open translation of animal benefits to human outcomes.
Angiotensin II (Ang II) plays a key role in the regulation of blood pressure and fluid homeostasis. Valsartan is a highly selective Ang II receptor blocker that specifically and selectively blocks Ang II at the AT1-receptor. In animal models, valsartan has shown positive effects on vasoconstriction, proliferation, remodelling, endothelial function and thrombogenesis, inflammation and atherosclerosis. These data are likely to be confirmed by the results of current clinical trials and valsartan is set to provide improved cardiovascular therapy in the future.
No takes yet. Share an insight, caveat, or question.
Marc de Gasparo (2000) reported a review. Valsartan was evaluated. Valsartan demonstrated positive effects on vasoconstriction, proliferation, remodelling, endothelial function, thrombogenesis, inflammation, and atherosclerosis in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: